Advertisement
GALT vs VIR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GALT is a Buy and VIR is a Hold.
GALT's RSI Indicator recovers from oversold territory
The RSI Indicator for GALT moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 27 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 62 cases where GALT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on GALT as a result. In 82 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for GALT just turned positive on November 09, 2026. Looking at past instances where GALT's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
Following a +15.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where GALT advanced for three days, in 195 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
GALT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
GALT moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GALT crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GALT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for GALT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.277) is normal, around the industry mean (3.498). P/E Ratio (-7.302) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. GALT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VIR in upward trend: price rose above 50-day moving average on October 26, 2026
VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 68 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for VIR just turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 32 of 41 cases over the following month. The odds of a continued upward trend are 78%.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 130 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for VIR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 27 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.498). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
GALT | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 13 Undervalued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 96 | |
PRICE GROWTH RATING 1..100 | 50 | 35 | |
P/E GROWTH RATING 1..100 | 20 | 81 | |
SEASONALITY SCORE 1..100 | 9 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GALT's Valuation (13) in the Biotechnology industry is in the same range as VIR (19) in the null industry. This means that GALT’s stock grew similarly to VIR’s over the last 12 months.
GALT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VIR (100) in the null industry. This means that GALT’s stock grew similarly to VIR’s over the last 12 months.
VIR's SMR Rating (96) in the null industry is in the same range as GALT (100) in the Biotechnology industry. This means that VIR’s stock grew similarly to GALT’s over the last 12 months.
VIR's Price Growth Rating (35) in the null industry is in the same range as GALT (50) in the Biotechnology industry. This means that VIR’s stock grew similarly to GALT’s over the last 12 months.
GALT's P/E Growth Rating (20) in the Biotechnology industry is somewhat better than the same rating for VIR (81) in the null industry. This means that GALT’s stock grew somewhat faster than VIR’s over the last 12 months.
| GALT | VIR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 80% |
| Advances ODDS (%) | 3 days ago 84% | 3 days ago 76% |
| Declines ODDS (%) | 13 days ago 87% | 10 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GALT’s FA Score shows that 2 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
- GALT’s FA Score: 2 green, 3 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GALT’s TA Score shows that 6 TA indicator(s) are bullish while VIR’s TA Score has 6 bullish TA indicator(s).
- GALT’s TA Score: 6 bullish, 4 bearish.
- VIR’s TA Score: 6 bullish, 4 bearish.
Price Growth
GALT (@Biotechnology) experienced а +0.90% price change this week, while VIR (@Biotechnology) price change was +17.20% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
GALT is expected to report earnings on Nov 13, 2026.
VIR is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GALT and
Correlation & Price change
A.I.dvisor tells us that GALT and ALT have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GALT and ALT's prices will move in lockstep.
| Ticker / NAME | Correlation To GALT | 1D Price Change % | ||
|---|---|---|---|---|
| GALT | 100% | -2.31% | ||
| ALT - GALT | 32% Poorly correlated | -8.49% | ||
| TAOX - GALT | 32% Poorly correlated | -5.15% | ||
| RNAC - GALT | 32% Poorly correlated | -1.85% | ||
| MGTX - GALT | 31% Poorly correlated | +1.37% | ||
| VIR - GALT | 31% Poorly correlated | -3.63% | ||
More | ||||
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | -3.63% | ||
| BEAM - VIR | 54% Loosely correlated | -6.92% | ||
| EDIT - VIR | 54% Loosely correlated | -8.91% | ||
| DNLI - VIR | 52% Loosely correlated | -2.36% | ||
| SLDB - VIR | 52% Loosely correlated | +2.14% | ||
| BCYC - VIR | 51% Loosely correlated | -2.12% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IPB | 24.92 | N/A | N/A |
| Merrill Lynch Depositor | |||
| BKWO | 37.72 | N/A | N/A |
| BNY Mellon Womens's Opportunities ETF | |||
| DLS | 84.72 | -0.14 | -0.16% |
| WisdomTree International SmallCap Dividend Fund (DLS) | |||
| APMU | 24.72 | -0.06 | -0.22% |
| ActivePassive Intermediate Municipal Bond ETF (APMU) | |||
| RDFI | 21.72 | -0.37 | -1.68% |
| Rareview Dynamic Fixed Income ETF (RDFI) | |||